Juvenescence’s market watch

While Juvenescence Ltd. is staying tight-lipped on whether crossover investors joined the first tranche of its series B round, the company did shed some light on its IPO plans and growing portfolio of aging-related assets.

The AI-based company, which creates and invests in new companies developing therapeutics for aging-related diseases, raised $46 million in the first tranche of a $100 million series B round on Jan. 17 from undisclosed investors...